11 December 2025
11 December 2025
The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.
Lynk Pharmaceuticals will receive an upfront payment and potential milestone payments that could reach $605m.
The approval is supported by outcomes from the pivotal Phase III FIBRONEER-ILD trial.
Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.
Arog’s Phase III trial of crenolanib met its primary endpoint and improved OS and EFS in patients with NPM1/FLT3 co‑mutated AML.
On market launch of the product, Formycon will receive a mid–double-digit-share of gross profits in the region.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
